The AI Act and Ethics in Pharma Advertising
With the EU AI Act fully in effect in 2026, German pharmaceutical advertising is subject to new transparency requirements.
Any advertising content generated by AI must be clearly labeled, and "High-Risk" AI systems used for patient profiling are subject to strict audits. German firms have responded by establishing AI Ethics Boards to oversee their advertising algorithms, ensuring that they do not inadvertently create biases or "filter bubbles" that exclude certain patient populations from life-saving information. Transparency about how data is used for targeting is now viewed by German consumers as a key indicator of a brand's trustworthiness and social responsibility.
2 Views